Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City.
A commercial line probe assay kit (Inno-LiPA Rif.TB) for rapid identification of mutations in the rpoB gene associated with rifampin resistance in Mycobacterium tuberculosis was evaluated with a collection of 51 rifampin-resistant strains. Nine distinct rpoB mutations were identified. Concordances with automated sequence results for five wild-type kit probes and four probes for specific mutations were 94.1 and 100%, respectively. Overall concordance of the line probe assay kit with phenotypic rifampin susceptibility testing results was 90.2%.
Cooksey
R C
RC
Division of AIDS, Sexually Transmitted Diseases, and Tuberculosis Laboratory Research, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. rccl@cdc.gov
Morlock
G P
GP
Glickman
S
S
Crawford
J T
JT
D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D012321:DNA-Directed RNA Polymerases / Q000235:genetics*; D004352:Drug Resistance, Microbial / Q000235:genetics*; D006801:Humans; D015336:Molecular Probe Techniques; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D009519:New York City / Q000453:epidemiology; D012293:Rifampin / Q000494:pharmacology*; D014376:Tuberculosis / Q000453:epidemiology / Q000382:microbiology*
D000904:Antibiotics, Antitubercular; D012321:DNA-Directed RNA Polymerases; C105078:RNA polymerase beta subunit; D012293:Rifampin